Research Article| Volume 47, ISSUE 4, P527-535, August 2020

Download started.


Periostin in middle ear mucosa according to eosinophilic otitis media severity: Middle ear pathology-based treatment



      Eosinophilic otitis media (EOM) is an intractable disorder associated with bronchial asthma and chronic rhinosinusitis with nasal polyposis. Periostin is an extracellular matrix protein secreted by fibroblasts in response to interleukin (IL)-4 and/or IL-13 and is a known marker for eosinophilic disorders. We assessed serum periostin levels and expression of periostin in the middle ear mucosa according to three grade of EOM severity (grade1 to 3).


      68 patients of blood and serum samples were corrected by whom diagnose bilateral EOM in Jichi Medical University Saitama Medical Center from January 2015 to June 2017.Immunohistochemical evaluation was performed to 18 EOM middle ears mucosa samples, which cauterized in tree groups and compared to that of chronic otitis media (COM).


      Serum periostin levels was significantly higher in EOM patients than in COM patients (EOM, 125.0 ± 45.5 ng/mL; COM, 79.4 ± 38.3 ng/mL; P<0.0001). The expression of periostin immunopositivity in the EOM middle ear mucosa was significantly greater in severe cases (grade3 samples) than others (grade1 and grade2 samples) (P <0.001 and P = 0.011, respectively). Periostin was expressed at the lamina propria especially in severe EOM cases and the cases had little response to glucocorticoids treatment.


      This study showed that periostin in the middle ear mucosa was correlated with EOM severity, and EOM with highly expressed periostin had difficulty in glucocorticoids treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Auris Nasus Larynx
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Iino Y.
        • Tomioka-Matsutani S.
        • Matsubara A.
        • Nakagawa T.
        • Nonaki M.
        Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease.
        Auris Nasus Larynx. 2011; 38: 456-461
        • Iino Y.
        Eosinophilic otitis media: a new middle ear disease.
        Curr Allergy Asthma Rep. 2008; 8: 525-530
        • Ueki S.
        • Ohta N.
        • Takeda M.
        • Konno Y.
        • Hirokawa M.
        Eosinophilic otitis media: the aftermath of eosinophil extracellular trap cell death.
        Curr Allergy Asthma Rep. 2017; 17: 33
        • Ohta N.
        • Ueki S.
        • Konno Y.
        • Hirokawa M.
        • Kubota T.
        • Tomioka-Matsutani S.
        • et al.
        ETosis-derived DNA trap production in middle ear effusion is a common feature of eosinophilic otitis media.
        Allergol Int. 2018; 67: 414-416
        • Azadarmaki R.
        • Westra W.
        • Prasad S.
        Eosinophilic mucin otomastoiditis and otopolyposis: a progressive form of eosinophilic otitis media.
        Ann Otol Rhinol Laryngol. 2015; 124: 752-756
        • Kanazawa H.
        • Yoshida N.
        • Yamamoto H.
        • Hara M.
        • Hasegawa M.
        • Matsuzawa S.
        • et al.
        Risk factors associated with severity of eosinophilic otitis media.
        Auris Nasus Larynx. 2014; 41: 513-517
        • Izuhara K.
        • Arima K.
        • Ohta S.
        • Suzuki S.
        • Inamitsu M.
        • Yamamoto K.
        Periostin in allergic inflammation.
        Allergol Int. 2014; 63: 143-151
        • Ohta N.
        • Ishida A.
        • Kurukami K.
        • Suzuki Y.
        • Kakehata S.
        • Onoet J.
        • et al.
        Expressions and roles of periostin in otolaryngological diseases.
        Allergol Int. 2014; 63: 171-180
        • Nishizawa H.
        • Matsubara A.
        • Nakagawa T.
        • Ohta N.
        • Izuhara K.
        • Shirasaki T.
        • et al.
        The role of periostin in eosinophilic otitis media.
        Acta Oto-laryngol. 2012; 132: 838-844
        • Izuhara K.
        • Nunomura S.
        • Nanri Y.
        • Ono J.
        • Takai
        • Kawaguchi A.
        Periostin: an emerging biomarker for allergic diseases.
        Allergy. 2019; 74: 2116-2128
        • Takayama G.
        • Arima K.
        • Kanaji T.
        • Toda S.
        • Tanaka H.
        • Shoji S.
        • et al.
        Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals.
        J Allergy Clin Immunol. 2006; 118: 98-104
        • Ishida A.
        • Ohta N.
        • Suzuki Y.
        • Kakehata S.
        • Okubo K.
        • Ikeda H.
        • et al.
        Expression of pendrin and periostin in allergic rhinitis and chronic rhinosinusitis.
        Allergol Int. 2012; 61: 589-595
        • Woodruff P.G.
        • Boushey H.A.
        • Dolganov G.M.
        • Barker C.S.
        • Yang Y.H.
        • Donnelly S.
        • et al.
        Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to glucocorticoids.
        Proc Natl Acad Sci USA. 2007; 104: 15858-15863
        • Kanemitsu Y.
        • Matsumoto H.
        • Mishima M.
        • KiHAC Respiratory Medicine Group
        Factors contributing to an accelerated decline in pulmonary function in asthma.
        Allergol Int. 2014; 63: 181-188
        • Kanemitsu Y.
        • Matsumoto H.
        • Izuhara K.
        • Tohda Y.
        • Kita H.
        • Horiguchi T.
        • et al.
        Increased periostin associates with greater airflow limitation in patients receiving inhaled glucocorticoids.
        J Allergy Clin Immunol. 2013; 132: 305-312
        • Fingleton J.
        • Travers J.
        • Bowles D.
        • Bowles D.
        • Strik R.
        • Siebers R.
        • et al.
        Serum periostin in obstructive airways disease: range, relationships and response to glucocorticoid.
        Eur Respir J. 2014; 44: 3873
        • Li W.
        • Gao P.
        • Zhi Y.
        • Wei X.
        • Yanfeng W.
        • Jinzhi Y.
        • et al.
        Periostin: its role in asthma and its potential as a diagnostic or therapeutic target.
        Respir Res. 2015; 16: 57
        • Jia G.
        • Erickson R.W.
        • Choy D.F.
        • Mosesova S.
        • Wu L.C.
        • Solberg O.D.
        • et al.
        Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.
        J Allergy Clin Immunol. 2012; 130: 647-654
        • Wechsler M.E.
        Current and Emerging Biologic Therapies for Asthma and COPD.
        Respir Care. 2018; 63: 699-707
        • Stankovic K.M.
        • Goldsztein H.
        • Reh D.D.
        • Platt M.P.
        • Metson R.
        Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma.
        Laryngoscope. 2008; 118: 881-889
        • Shiono O.
        • Sakuma Y.
        • Komatsu M.
        • Hirama M.
        • Yamashita Y.
        • Ishitoya J.
        • et al.
        Differential expression of periostin in the nasal polyp may represent distinct histological features of chronic rhinosinusitis.
        Auris Nasus Larynx. 2015; 42: 123-127
        • Shoda T.
        • Futamura K.
        • Kobayashi F.
        • Saito H.
        • Matsumoto K.
        • Matsuda A.
        Cell type-dependent effects of glucocorticoid on periostin production by primary human tissue cells.
        Allergy. 2013; 68: 1467-1470